von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.
about
von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand diseaseQuinine- and quinidine-dependent antiplatelet antibodies. Requirement of factor VIII-related antigen for platelet damage and for in vitro transformation of lymphocytes from patients with drug-induced thrombocytopeniaPlatelets have more than one binding site for von Willebrand factor.Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit.The molecular biology of von Willebrand disease.Interaction of von Willebrand factor with human platelets in the plasma milieuDivergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cellsEndothelial cell synthesis of von Willebrand antigen II, von Willebrand factor, and von Willebrand factor/von Willebrand antigen II complex.Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.von Willebrand factor propeptide: biology and clinical utilityIntercellular calcium communication regulates platelet aggregation and thrombus growth.Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).Carbohydrate of the factor VIII/von Willebrand factor in von Willebrand's disease.Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin.Translational medicine advances in von Willebrand disease.Molecular biology of von Willebrand factor.Interaction between platelet glycoprotein Ibalpha and filamin-1 is essential for glycoprotein Ib/IX receptor anchorage at high shear.New methods in coagulation.Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit.Bidirectional integrin alphaIIbbeta3 signalling regulating platelet adhesion under flow: contribution of protein kinase C.Distinct glycoprotein Ib/V/IX and integrin alpha IIbbeta 3-dependent calcium signals cooperatively regulate platelet adhesion under flow.RhoA sustains integrin alpha IIbbeta 3 adhesion contacts under high shear.Signaling role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FcR gamma chain and Fc gamma RIIA.Importance of temporal flow gradients and integrin alphaIIbbeta3 mechanotransduction for shear activation of platelets.Application of a strain rate gradient microfluidic device to von Willebrand's disease screening.The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells.
P2860
Q33478102-E8F2B380-64B8-45CB-8755-36897613984EQ33481532-DC0DFF4F-2931-4099-B3B2-D339D197E089Q33821754-41ED6F82-5A6D-49BD-9546-30AC49488A80Q34197102-3FC2B6A4-D56E-4150-A4E8-8B33F5793E60Q34421530-38A1B29B-A59D-4817-B2BB-97F3C10EAE95Q34602783-392E6A79-D81F-470C-97DE-12E4CE5824CAQ34609277-294AE744-1AC7-468F-9FDA-5EE79BA36232Q34624113-7EAB2FA4-EB34-43B5-AEBF-A4570BFD45A5Q35848737-9FB703FA-CD67-49AC-88CE-C4635F28A10DQ36143225-A7C97454-F76D-487C-BECD-6CE95942DB60Q36323179-A60CAA56-9E81-4FCA-922A-E5861FAB6958Q36658007-58631AE1-5F04-43D1-AFD0-A25E2E412E53Q37017221-D220A6EE-471C-4BA8-A47B-6FAAECB53F15Q37023086-7EC9C27C-AEDC-484F-B5CA-951766385E76Q37034062-734A25FF-FDEB-4B81-92D8-DEE015B0FDDEQ37602563-E96A8873-D537-4D1C-B9EC-6B42165D3752Q37711733-050805AF-6865-4142-929F-DD864AB24FBDQ38294908-7687EF17-FE42-4868-9734-E4349979BE77Q40219568-2C17E96A-6637-46B6-953D-0624927515E1Q41849328-54206FAE-5C91-487B-B7FB-0217086F5994Q43002844-6A80FEBF-C589-479E-A68E-60DEF417142BQ43802417-6E13BF7F-D19C-446C-AA43-063874948B57Q43878513-60BAAE77-0198-4F66-9834-CB969FBB90CAQ44482191-2907A43F-B5D6-446E-B713-8C176ED89B2BQ45258114-A5F168C7-4D81-4AF0-BA5E-C5090ADAE90BQ47975691-463B26D7-C2DE-41FE-8D11-3580378EA727Q53814684-08FE4110-B2F7-4F64-B020-A0ACF1422649
P2860
von Willebrand's disease antigen II. A new plasma and platelet antigen deficient in severe von Willebrand's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1978
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
von Willebrand's disease antig ...... vere von Willebrand's disease.
@en
von Willebrand's disease antig ...... vere von Willebrand's disease.
@nl
type
label
von Willebrand's disease antig ...... vere von Willebrand's disease.
@en
von Willebrand's disease antig ...... vere von Willebrand's disease.
@nl
prefLabel
von Willebrand's disease antig ...... vere von Willebrand's disease.
@en
von Willebrand's disease antig ...... vere von Willebrand's disease.
@nl
P2860
P356
P1476
von Willebrand's disease antig ...... vere von Willebrand's disease.
@en
P2093
Montgomery RR
Zimmerman TS
P2860
P304
P356
10.1172/JCI109070
P407
P577
1978-06-01T00:00:00Z